Fate Therapeutics Inc. (NASDAQ:FATE) shares shot up 4.5% during trading on Friday . The stock traded as high as $2.12 and last traded at $2.07, with a volume of 527,613 shares traded. The stock had previously closed at $1.98.

Several research firms have commented on FATE. BMO Capital Markets began coverage on shares of Fate Therapeutics in a research note on Monday, April 11th. They set an “outperform” rating and a $4.00 price objective for the company. Leerink Swann reaffirmed an “outperform” rating and set a $4.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, June 21st. HC Wainwright began coverage on shares of Fate Therapeutics in a research note on Thursday. They set a “buy” rating and a $9.00 price objective for the company. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Fate Therapeutics has an average rating of “Buy” and a consensus target price of $6.17.

The firm’s market capitalization is $59.75 million. The firm has a 50 day moving average of $1.78 and a 200-day moving average of $1.86.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. Analysts predict that Fate Therapeutics Inc. will post ($1.23) EPS for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.